Form 4: FMC Exec Sells Shares Under 10b5-1 Plan
Insider Trading Report
FMC Corporation's Executive VP & Chief HRO, Jacqueline Scanlan, sold 1,510 shares of common stock for $37.49 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Jacqueline Scanlan, Executive VP & Chief HRO of FMC Corporation, sold 1,510 shares of FMC common stock.
- The transaction occurred on August 18, 2025, at a price of $37.49 per share.
- Following this sale, Scanlan beneficially owns 36,834 shares of FMC common stock.
- The sale was executed pursuant to a Rule 10b5-1(c) trading plan, indicating it was pre-scheduled.
Sentiment
Score: 5
Explanation: A neutral sentiment. While an insider sale can sometimes be viewed negatively, the disclosure that it was conducted under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, adverse information. It's a routine part of executive compensation and financial planning.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, which suggests a pre-planned transaction rather than a reaction to new, non-public information.
Negatives
- An insider sale, even if pre-planned, reduces the executive's direct equity stake in the company.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction is specific to an individual executive's equity management and does not directly reflect broader industry trends or competitive dynamics within the chemicals sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | Jacqueline Scanlan granted a Power of Attorney to Sara Ponessa and Zakiya Barnett to execute and file Forms 3, 4, and 5 on her behalf with the SEC. | 06/02/2025 | Streamlines the process for executive compliance with Section 16(a) of the Securities Exchange Act of 1934, ensuring timely and accurate filings. |
Stakeholder Impact
- Shareholders: A minor reduction in an executive's direct ownership, but mitigated by the 10b5-1 plan.
- Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.
Key Dates
| Date | Description |
|---|---|
| 06/02/2025 | Date Power of Attorney was executed by Jacqueline Scanlan. |
| 08/18/2025 | Date of common stock transaction (sale). |
| 08/19/2025 | Date Form 4 was signed by attorney-in-fact. |
Recommendation
holdThis Form 4 filing reports a routine, pre-planned sale of a small portion of an executive's holdings under a 10b5-1 plan. Such transactions are common for executive financial planning and do not typically signal a change in company fundamentals or outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
FMC Corporation, FMC, Insider Trading, Form 4, Jacqueline Scanlan, Stock Sale, 10b5-1 Plan, Executive Compensation, Chemicals Industry
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.